Join this Featured Workgroup!
Elite Investors

This group is for elite investors and traders that are dedicated to participating in an active community that wants to learn from each other, share their research, and work together to do deep analysis of securities. The moderator of this group taught securities analysis at UCLA and is dedicated to helping other investors improve their abilities.

In this private group, membership is restricted and regular contributions are required. Any member not contributing on a regular basis will be removed to make room for a new member.

In your application messsage, please share your background and what you can contribute to the group.


SecurityXTNT / Xtant Medical Holdings, Inc. (98420P100)
IndustryBiological Products, Except Diagnostic Substances (Biotech)
Institutional Owners2
Institutional Shares297,627 - 2.28%
Common Shares Outstanding13,077,468 shares (as of 2018-03-31)
Institutional Value$ 2,337,000 USD

Institutional Stock Ownership and Shareholders()

XTNT / Xtant Medical Holdings, Inc. Institutional Ownership

Xtant Medical Holdings, Inc. (AMEX:XTNT) has 2 institutional investors and shareholders that have filed 13D/G or 13F forms with the Securities Exchange Commission (SEC). These institutions hold a total of 297,627 shares. Largest shareholders include Bruce & Co., Inc., and BlackRock Fund Advisors.
Xtant Medical Holdings, Inc. (AMEX:XTNT) ownership structure shows current positions in the company by institutions and funds, as well as latest changes in position size. Major shareholders can include individual investors, mutual funds, hedge funds, or institutions. The Schedule 13D indicates that the investor holds more than 5% of the company and intends to actively pursue a change in business strategy. Schedule 13G indicates a passive investment of over 5%. Green rows indicate new positions. Red rows indicate closed positions. Click the link icon to see the full transaction history.

Embed this chart! (it updates automatically)
<a href="https://fintel.io/so/us/xtnt"><img src="https://images.fintel.io/us-xtnt-so.png" alt="XTNT / Xtant Medical Holdings, Inc. Institutional Ownership"><a>

File DateFormInvestor Opt Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
($1000)
Current Value
($1000)
Change
(Percent)
2018-02-14 13F-HR GOLDMAN CAPITAL MANAGEMENT INC 43,000 0 -100.00 31 0 -100.00
2018-05-15 13F-HR UBS Group AG 68,000 0 -100.00 39 0 -100.00
2018-05-09 13F-HR Cambridge Investment Research Advisors, Inc. 64,280 0 -100.00 37 0 -100.00
2018-05-14 13F-HR Renaissance Technologies LLC 291,892 0 -100.00 167 0 -100.00
2018-05-15 13F-HR BANK OF AMERICA CORP /DE/ 574 0 -100.00 0 0
2018-05-14 13F-HR NORTHWESTERN MUTUAL WEALTH MANAGEMENT CO 41,693 0 -100.00 24 0 -100.00
2018-05-15 13F-HR ORBIMED ADVISORS LLC 4,754,386 0 -100.00 272 0 -100.00
2018-05-09 13F-HR BlackRock Inc. 1,455 0 -100.00 1 0 -100.00
2018-05-14 13F-HR/A CITADEL ADVISORS LLC 13,659 0 -100.00 8 0 -100.00
2018-05-15 13F-HR VANGUARD GROUP INC 58,150 0 -100.00 33 0 -100.00
2018-05-10 13F-HR CALIFORNIA PUBLIC EMPLOYEES RETIREMENT SYSTEM 27,720 0 -100.00 16 0 -100.00
2018-04-23 13F-HR PERKINS CAPITAL MANAGEMENT INC 380,734 0 -100.00 218 0 -100.00
2018-05-02 13F-HR FTB Advisors, Inc. 4,000 0 -100.00 2 0 -100.00
2018-05-18 13F-HR/A ROYAL BANK OF CANADA 1,167 0 -100.00 1 0 -100.00
2018-05-03 13F-HR Texas Yale Capital Corp. 10,000 0 -100.00 6 0 -100.00
2017-02-10 13F-HR BlackRock Fund Advisors 1,224 1,455 18.87 1 1 0.00
2018-05-02 13F-HR OUTFITTER ADVISORS, LTD. 35,755 0 -100.00 20 0 -100.00
2018-05-14 13F-HR MORGAN STANLEY 6,850 0 -100.00 4 0 -100.00
2018-05-15 13F-HR SUSQUEHANNA INTERNATIONAL GROUP, LLP 10,241 0 -100.00 6 0 -100.00
2018-05-09 13F-HR NORTHERN TRUST CORP 2,558,863 0 -100.00 1,467 0 -100.00
2018-05-15 13F-HR Bruce & Co., Inc. 296,172 2,336
XTNT : Xtant Medical Holdings Stock Analysis and Research Report

2017-10-26 - Asif

Xtant Medical Holdings, Inc. develops, manufactures and markets class-leading regenerative medicine products and medical devices for domestic and international markets. Xtant products serve the specialized needs of orthopedic and neurological surgeons, including orthobiologics for the promotion of bone healing, implants and instrumentation for the treatment of spinal disease, tissue grafts for the treatment of orthopedic disorders, and biologics to promote healing following cranial, and foot and ankle surgeries. Xtant believes the following competitive strengths will be key drivers of future growth of Xtant: Portfolio of Proprietary Technologies: Xtant has developed a comprehensive portfolio of products that address a broad array of spinal pathologies, anatomies and surgical approaches in the complex spine and minimally invasive surgery (“MIS”) markets. To protect company innovative technologies and techniques, Xtant maintains and continues to grow its intellectual property por...

Related Articles

KTOV: Kitov Pharamceuticals Holdings Analysis and Research Report

2018-07-17 - Asif

History and Development of the Company Kitov Pharma was incorporated under the laws of the State of Israel (under a previous name) on August 12, 1968 and its ordinary shares were originally listed for trading on the TASE in 1978. The company's ordinary shares are currently traded on the TASE under the symbol “KTOV”, and its ADSs and its public warrants are traded on NASDAQ under the symbols “KTOV” and “KTOVW”, respectively. In October 2012, the District Court in Lod, Israel approved the creditors arrangement in accordance with Section 350 of the Companies Law in order to effectuate the sale by Kitov Pharma (then known as Mainrom Line Logistics Ltd.) of all its activities, assets, rights, obligations and liabilities to a private company held by its then controlling shareholders, and all rights of Kitov Pharma’s creditors against it were extinguished. The sale was made pursuant to an arrangement between Kitov Pharma and its creditors. Following such sale and a related cash...

ATHX: Athersys Analysis and Research Report

2018-07-17 - Asif

Overview and Recent Developments Athersys is an international biotechnology company that is focused primarily in the field of regenerative medicine. The company's MultiStem® cell therapy, a patented and proprietary allogeneic stem cell product, is its lead platform product and is currently in later-stage clinical development. The company's current clinical development programs are focused on treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, certain pulmonary conditions and other conditions where the current standard of care is limited or inadequate for many patients, particularly in the critical care segment. Current Programs By applying its proprietary MultiStem cell therapy product, the company established therapeutic product development programs treating neurological conditions, cardiovascular disease, inflammatory and immune disorders, and other conditions. The company's programs in the clinical development stage include ...

CYTX: Cytori Therapeutics Analysis and Research Report

2018-07-16 - Asif

General The company's objective is to build a profitable and growing specialty therapeutics company. To meet this objective, Cytori Therapeutics has acquired and are developing two technology platforms that hold promise for treating millions of patients and represent significant potential for increasing shareholder value. The company's current corporate activities fall substantially into advancing these platforms: Cytori Nanomedicine and Cytori Cell Therapy. The Cytori Nanomedicine platform features a versatile liposomal nanoparticle technology for drug encapsulation that has thus far provided the foundation to bring two promising drugs into mid/late stage clinical trials. Nanoparticle encapsulation is promising because it can help improve the delivery and metabolism of many drugs, thus potentially enhancing the therapeutic profile and patient benefits. The company's lead drug candidate, ATI-0918 is a generic version of pegylated liposomal encapsulated doxorubicin. Pegyl...

Related News Stories

Xtant's (XTNT) CEO Carl O'Connell on Q1 2018 Results - Earnings Call Transcript

2018-05-09 seekingalpha
Xtant Medical Holdings, Inc. (NYSEMKT:XTNT) Q1 2018 Earnings Conference Call May 9, 2018 9:00 AM ET (56-1)

Xtant's (XTNT) CEO Carl O'Connell on Q4 2017 Results - Earnings Call Transcript

2018-04-03 seekingalpha
Xtant Medical Holdings, Inc. (NYSEMKT:XTNT) Q4 2017 Results Earnings Conference Call April 3, 2018 9:00 AM ET (56-1)

Xtant Medical Holdings, Inc. 2017 Q4 - Results - Earnings Call Slides

2018-04-03 seekingalpha
The following slide deck was published by Xtant Medical Holdings, Inc. in conjunction with their 2017 Q4 earnings call. (56-0)

CUSIP: 98420P100